TC
ALT icon

TFS Capital’s Altimmune ALT Stock Holding History

TFS Capital’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,510
Closed -$1.47M – 651
2016
Q4 		$1.47M Buy
1,510
+1,283
+565% +$1.15M 0.39% 53
2016
Q3 		$197K Sell
227
-478
-68% -$375K 0.05% 560
2016
Q2 		$516K Buy
705
+646
+1,095% +$442K 0.09% 365
2016
Q1 		$34K Buy
+59
New +$30.2K ﹤0.01% 962

Other funds holding ALT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FQ
First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

TFS Capital's ALT Position: Q1 2017 in Review

TFS Capital sold out of Altimmune (ALT) in Q1 2017, closing a stake of 1,510 shares — an estimated $1.47M sold.

TFS Capital first reported a position in ALT in Q1 2016 and held it in 4 quarters. The position peaked at $1.47M in Q4 2016. 71 funds tracked by Wall St. Rank hold ALT as of Q1 2017.

  • TFS Capital reported no remaining Altimmune position as of Q1 2017 after selling out during the quarter.
  • TFS Capital sold 1,510 Altimmune shares in Q1 2017, an estimated $1.47M.
  • TFS Capital first reported a position in Altimmune in Q1 2016 and held it in 4 quarters.
  • TFS Capital's Altimmune position peaked at $1.47M in Q4 2016.
  • 71 funds tracked by Wall St. Rank held Altimmune as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.